RE:RE:RE:" Missing 18 Pending patients data"CancerSlayer, thank's for your response, I like it when somebody take the time to read my post and point ou some interogations point that they have.
If you take the time to read the April 29,2020 Newsrelease, TLT said " To date 8 patients have been treated at UHN and 4 patients treated at MUHC for a total of 12 patients".
Note: These 12 patients are undertreated patients.
In the same Newsrelease TLT said "No new patients will be enrolled or treated at any Canadian clinical study site, nor will any existing patient curently enrolled in the clinical study site be treated a second time , until the clinical study site re-commence operation.
Note: The above mean that the 12 undertreated patients wil not be treated until the study site re-commence operation.
In the August 12,2020 Newsrelease TLT said " Three out of 4 of its Canadian clinical study site have re-commenced new patient enrollement and treatment in the Company's Phase11 non-Muscle invasive Bladder cancer.
In the same Newsrelease TLT said..
"On a go forward basis, all future and existing patients to be enroled and treated (initial and second treatment) in Study11 will be treated using the Study11 treatment optimization ".
Note; The above indicate that the 8 undertreated patients are included in the existing patients and will be treated a second time using the optimized treatment protocol.
From the 3Q2021 Quaterly Newsletter(page 5) TLT said " In summary, for the patients who received the primary optimized treatment versus the original Study11 treatment, there is a 5% increase in CR and a 75% decrease in NR(non-response).
Note: The original Study11 treatment had 24%NR(no-response) - 75% = 6%NR(non-response). In your post you said that the 18 patients are NR(non-response) patients, 18 NR patients /29 patients give us a 63% NR(non-response), we are very far from the 6%NR of the optimized patients group proclaimed by TLT.
I must admit that trying to understand TLT newsletter is quite a challenge even for the best of us, but I stand by my numbers, the 8 undertreated patients have been treated with the optimized treatment protocol, and there is no undertreated patients left in the Study11 trial.